<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417194</url>
  </required_header>
  <id_info>
    <org_study_id>L-2015-310</org_study_id>
    <nct_id>NCT02417194</nct_id>
  </id_info>
  <brief_title>Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma</brief_title>
  <official_title>Prospective Cohort Study for the Impact of Preoperative Glycemic Control Status Measured by HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of preoperative glycemic control measured by HbA1c on renal cell carcinoma (RCC)&#xD;
      outcome remains controversial. Thus, the investigators aim to examine the association of&#xD;
      preoperative glycemic control with oncologic outcomes after radical or partial nephrectomy.&#xD;
      The investigators will prospectively collect the relevant data including preoperative HbA1c&#xD;
      in 238 patients of RCC patients undergoing nephrectomy. The associations between clinical&#xD;
      variables and risk of adverse pathological features and disease recurrence will be tested&#xD;
      using a multivariate logistic regression and multiple Cox-proportional hazards model,&#xD;
      respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This is the observational study as the single institutional, prospective cohort study.&#xD;
           The investigators prospectively collect the clinicopathological information of the&#xD;
           patients with renal cell carcinoma (RCC) undergoing partial or radical nephrectomy.&#xD;
&#xD;
        -  Particularly, the investigators check the variables, including age at surgery, body mass&#xD;
           index, sex, comorbidities, preoperative HbA1c levels, blood urea nitrogen&#xD;
           (BUN)/creatinine levels, estimated-GFR, clinical TMN staging by CT scan, final&#xD;
           pathological results (TMN stage, histology, and Fuhrman nuclear grade), warm ischemic&#xD;
           time and surgical margin status (in the case of partial nephrectomy), postoperative&#xD;
           recurrence and distant metastasis, renal function changes during follow-up periods.&#xD;
&#xD;
        -  The study protocol is same with routine follow-up schedule of the patients with RCC&#xD;
           treated with nephrectomy. Typically, the investigators check the patients at 1, 3, 6,&#xD;
           12, 18, 24, 30 and 36 months. However, according to the patients status and preference,&#xD;
           follow-up schedule can be changed within 3 months at specific time points. Because the&#xD;
           present study is the observational cohort study, not intervention study, subtle changes&#xD;
           of follow-up schedule would not affect on the primary outcomes.&#xD;
&#xD;
        -  Importantly, preoperative HbA1c should be checked within 1 month before operation, same&#xD;
           as the routine preoperative laboratory tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>TMN stage</measure>
    <time_frame>within 2 weeks after surgery</time_frame>
    <description>Pathological outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fuhrman (nuclear) grade</measure>
    <time_frame>within 2 weeks after surgery</time_frame>
    <description>Pathological outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>postoperative up to 3 years</time_frame>
    <description>Oncological outcome: recurrence-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative renal function as assessed by estimated glomerular filtration rate (GFR)</measure>
    <time_frame>postoperative up to 3 years</time_frame>
    <description>estimated-GFR</description>
  </secondary_outcome>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Pathology</condition>
  <condition>Treatment Outcome</condition>
  <condition>Hemoglobin A1c Protein, Human</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Enrolled patients should be diagnosed with renal cell carcinoma by ultrasonography and/or&#xD;
        CT scan, MRI. In addition, the participants should be treated with radical or partial&#xD;
        nephrectomy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Renal cell carcinoma (RCC) by image work-up such as CT scan&#xD;
&#xD;
          -  Clinically localized RCC&#xD;
&#xD;
          -  Aged over 20 years&#xD;
&#xD;
          -  Patients undergoing radical or partial nephrectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  distant metastasis, preoperatively&#xD;
&#xD;
          -  preoperative targeted therapy&#xD;
&#xD;
          -  preoperative immunotherapy&#xD;
&#xD;
          -  medications affecting glucose status other than diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyunggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Kyu Hong, M.D, Ph.D</last_name>
      <phone>+82-31-787-7343</phone>
      <email>hsk823@chol.com</email>
    </contact>
    <contact_backup>
      <last_name>Jae-kyung Oh, B.S.</last_name>
      <phone>+82-31-787-2654</phone>
      <email>r1414@snubh.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>April 6, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Sung Kyu Hong</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Renal cell carcinoma</keyword>
  <keyword>hemoglobin A1c protein</keyword>
  <keyword>Pathologic outcomes</keyword>
  <keyword>Oncological outcomes</keyword>
  <keyword>Nephrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

